| Symbol | ASND |
|---|---|
| Name | ASCENDIS PHARMA A/S |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | TUBORG BOULEVARD 12, HELLERUP, DK-2900, Denmark |
| Telephone | +45 70222244 |
| Fax | — |
| — | |
| Website | https://www.ascendispharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firms product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China. Additional info from NASDAQ: |
2026-04-21 20:31
Ascendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028
Read more
2026-04-20 10:00
New Form 8-A12B/A - Ascendis Pharma A/S <b>Filed:</b> 2026-04-20 <b>AccNo:</b> 0001193125-26-162865 <b>Size:</b> 14 KB
Read more
2026-04-20 07:50
NASDAQ traded attribute type Security_Name was changed. Previous value: Ascendis Pharma A/S - American Depositary Shares. New value: Ascendis Pharma A/S - Ordinary Share.
Read more
2026-04-20 07:50
ASND attributes changed: Attr: Sec_name Ascendis Pharma A/S - American Depositary Shares -> Ascendis Pharma A/S - Ordinary Share;
Read more
2026-04-20 07:50
NASDAQ symbol attribute type Security_Name was changed. Previous value: Ascendis Pharma A/S - American Depositary Shares. New value: Ascendis Pharma A/S - Ordinary Share.
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07221851 | Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compare… | Phase3 | Turner Syndrome | Recruiting | 2025-12-12 | 2029-03-01 | ClinicalTrials.gov |
| NCT06433557 | A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Nave… | Phase2 | Achondroplasia | Active_Not_Recruiting | 2024-07-26 | 2027-11-01 | ClinicalTrials.gov |
| NCT05929807 | A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of… | Phase2 | Achondroplasia | Enrolling_By_Invitation | 2023-06-21 | 2039-03-01 | ClinicalTrials.gov |
| NCT05246033 | A Dose Escalation Trial Evaluating Safety, Efficacy, and Pharmacokinetics of Mu… | Phase2 | Achondroplasia | Active_Not_Recruiting | 2022-01-05 | 2024-03-01 | ClinicalTrials.gov |
| NCT04799054 | A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients Wi… | Phase1 | Advanced Solid Tumor | Terminated | 2021-03-18 | 2025-12-02 | ClinicalTrials.gov |
| NCT03344458 | A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children… | Phase3 | Growth Hormone Deficiency, Pediatric | Completed | 2017-12-19 | 2023-02-21 | ClinicalTrials.gov |
| NCT01947907 | Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekl… | Phase2 | Growth Hormone Deficiency (GHD) | Completed | 2013-07-01 | 2015-09-01 | ClinicalTrials.gov |
| NCT01247675 | A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) i… | Phase2 | Adult Growth Hormone Deficiency | Completed | 2010-11-01 | 2011-05-01 | ClinicalTrials.gov |
Total clinical trials: 8
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05820672 |
| Placebo for navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Palopegteriparatide Control Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Palopegteriparatide Experimental Arm | Other | Phase PHASE3 | Hypoparathyroidism | RECRUITING | NCT07081997 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05820672 |
| Placebo for navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05820672 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Placebo for navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Placebo for navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05820672 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Placebo for navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05820672 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Placebo for navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| No intervention | Other | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05820672 |
| Somatropin Pen Injector | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Lonapegsomatropin [SKYTROFA®] | Other | Phase PHASE3 | Turner Syndrome | RECRUITING | NCT07221851 |
| Placebo for navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Navepegritide | Other | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Palopegteriparatide | Other | Preclinical | Hypoparathyroidism | RECRUITING | NCT07264634 |
| Palopegteriparatide | DRUG | Preclinical | Hypoparathyroidism | RECRUITING | NCT07345494 |
| Placebo for navepegritide | DRUG | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06732895 |
| Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections | DRUG | Phase PHASE2 | Achondroplasia | ACTIVE_NOT_RECRUITING | NCT06433557 |
| Placebo for Navepegritide | DRUG | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06079398 |
| Navepegritide | DRUG | Phase PHASE2 | Achondroplasia | RECRUITING | NCT06079398 |
| No intervention | OTHER | Preclinical | Growth Hormone Deficiency | RECRUITING | NCT05820672 |
| Palopegteriparatide (TransCon PTH) | DRUG | Preclinical | Hypoparathyroidism | APPROVED_FOR_MARKETING | NCT05654701 |
| Trastuzumab emtansine (T-DM1) | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| Trastuzumab | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| Surgery | PROCEDURE | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| Chemotherapy drug | DRUG | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT05081609 |
| TransCon IL-2 β/γ | DRUG | Phase PHASE2 | Head and Neck Neoplasms | TERMINATED | NCT05980598 |
| Pembrolizumab | DRUG | Phase PHASE2 | Head and Neck Neoplasms | TERMINATED | NCT05980598 |
| TransCon TLR7/8 Agonist | DRUG | Phase PHASE2 | Head and Neck Neoplasms | TERMINATED | NCT05980598 |
| Somatropin | DRUG | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| Lonapegsomatropin | BIOLOGICAL | Phase PHASE2 | Turner Syndrome | ACTIVE_NOT_RECRUITING | NCT05690386 |
| daily hGH | DRUG | Phase PHASE3 | Growth Hormone Deficiency | UNKNOWN | NCT04326374 |
| Placebo for TransCon CNP | DRUG | Phase PHASE2 | Achondroplasia | COMPLETED | NCT05598320 |
| TransCon CNP | DRUG | Phase PHASE2 | Achondroplasia | ENROLLING_BY_INVITATION | NCT05929807 |
| TransCon Treprostinil | DRUG | Phase PHASE1 | Healthy Volunteers | TERMINATED | NCT03803163 |
| TransCon hGH | DRUG | Phase PHASE3 | Growth Hormone Deficiency | UNKNOWN | NCT04326374 |
| Once daily subcutaneous injection of Genotropin | DRUG | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT02781727 |
| Once weekly subcutaneous injection of TransCon hGH | DRUG | Phase PHASE3 | Growth Hormone Deficiency, Pediatric | COMPLETED | NCT02781727 |
| ACP-001 | DRUG | Phase PHASE2 | Growth Hormone Deficiency (GHD) | COMPLETED | NCT01947907 |
| Omnitrope | DRUG | Phase PHASE2 | Adult Growth Hormone Deficiency | COMPLETED | NCT01247675 |
| ACP-001 (TransCon hGH) | DRUG | Phase PHASE2 | Adult Growth Hormone Deficiency | COMPLETED | NCT01247675 |
| Human Growth Hormone | DRUG | Phase PHASE2 | Growth Hormone Deficiency (GHD) | COMPLETED | NCT01947907 |
| Placebo | OTHER | Phase PHASE3 | Growth Hormone Deficiency | COMPLETED | NCT04615273 |
| ACP-001 (TransCon PEG hGH) | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT01010425 |
Total products: 76